LRMR
Larimar Therapeutics, Inc.NASDAQHealthcare$4.79+2.35%ClosedMarket Cap: $409.9M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.51
P/S
0.00
EV/EBITDA
-2.06
DCF Value
$1.06
FCF Yield
-26.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-137.7%
ROA
-113.6%
ROIC
-210.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-62.5M | $-0.73 |
| FY 2025 | $0.00 | $-165.7M | $-2.27 |
| Q3 2025 | $0.00 | $-47.7M | $-0.61 |
| Q2 2025 | $0.00 | $-26.2M | $-0.41 |
Analyst Ratings
View AllWedbushOutperform
2026-03-20CitigroupBuy
2026-02-25OppenheimerOutperform
2025-10-02BairdOutperform
2025-09-30WedbushOutperform
2025-09-30Trading Activity
Insider Trades
View AllFlynn James Edirector, 10 percent owner, other: * Director by Deputization
BuyMon Mar 02
Flynn James Edirector, 10 percent owner, other: * Director by Deputization
BuyMon Mar 02
Flynn James Edirector, 10 percent owner, other: * Director by Deputization
BuyMon Mar 02
Flynn James Edirector, 10 percent owner, other: * Director by Deputization
BuyMon Mar 02
Hamilton Thomas Edwarddirector
BuyMon Mar 02
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.02
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.